Amalgamated Financial’s BioXcel Therapeutics BTAI Stock Holding History

Amalgamated Financial’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$59K	Buy	+176	New	+$51K	﹤0.01%	2342

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Amalgamated Financial's BTAI Position: Q1 2022 in Review

Amalgamated Financial opened a new position in BioXcel Therapeutics (BTAI) in Q1 2022: 176 shares worth $59K. The stake represents ﹤0.01% of the portfolio and ranks #2342 among its holdings.

96 funds tracked by Wall St. Rank hold BTAI as of Q1 2022.

Amalgamated Financial held 176 shares of BioXcel Therapeutics worth $59K as of Q1 2022.
BioXcel Therapeutics was a new Amalgamated Financial position in Q1 2022.
BioXcel Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2342 holding.
96 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.